|
| Wednesday, October 12, 2016 |
|
|
Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 |
| Eisai Co., Ltd. announced today that a presentation on the results of a Phase Ib clinical study of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in combination with the anti-PD-1 antibody pembrolizumab developed by Merck & Co., Inc., known as MSD outside the United States and Canada, in patients with selected solid tumors was given at the European Society for Medical Oncology (ESMO) Congress held from October 7 to 11. more info >> |
|
| Tuesday, October 4, 2016 |
|
|
Exclusive Licensing Agreement for In-house Developed Monoclonal Antibody Farletuzumab in Latin America Concluded with Eurofarma Laboratorios S.A. |
| Eisai Co., Ltd. announced today that its research subsidiary Morphotek, Inc. has signed an exclusive licensing agreement with Eurofarma Laboratorios S.A. to develop and commercialize the monoclonal antibody farletuzumab as a potential anticancer agent in Latin America. more info >> |
|
|
Launch of Uritos Tablets for Overactive Bladder in Thailand |
| Eisai Co., Ltd. and KYORIN Holdings, Inc. announced today that Eisai's Thai subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched Uritos Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, in Thailand. more info >> |
|
|
BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched BELVIQ XR 20mg tablets, a new once-daily formulation of BELVIQ (generic name: lorcaserin hydrochloride) for chronic weight management in the United States. more info >> |
|
| Friday, September 30, 2016 |
|
|
Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line Therapy for Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced ienttoday the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma. more info >> |
|
| Thursday, September 29, 2016 |
|
|
Eisai to Present Latest Data on Lenvatinib and Eribulin at ESMO Congress 2016 |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical and pre-clinical data on lenvatinib mesylate and eribulin mesylate will be presented during the European Society for Medical Oncology (ESMO) Congress 2016 more info >> |
|
| Wednesday, September 28, 2016 |
|
|
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Treatment of non-infectious Uveitis |
| AbbVie GK and Eisai Co., Ltd. today announced the additional approval for a new indication of HUMIRA, a fully human anti-TNF-alha monoclonal antibody formulation, in the treatment of non-infectious intermediate, posterior and panuveitis. more info >> |
|
|
Eisai Commences Provision of "EMILY" Smartphone App to Support Living with Epilepsy in Japan |
| Eisai Co., Ltd. announced today that it has commenced provision of the "EMILY" smartphone app in Japan to enable people with epilepsy and their families to enjoy greater peace of mind. more info >> |
|
|
Eisai Submits Supplemental Application for Partial Label Change for Antiepileptic Drug Fycompa |
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has submitted a supplemental application for its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel) proposing the inclusion in labelling of a description of use as monotherapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older to the U.S Food and Drug Administration (FDA) based on new FDA policy.
more info >> |
|
| Thursday, September 15, 2016 |
|
|
Eisai Receives License for New Indication for Anticancer Agent Kisplyx (Lenvatinib Mesylate) for Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced that its European regional headquarters Eisai Europe Ltd. has received license from the European Commission for anticancer agent Kisplyx in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy. more info >> |
|
|
|
